CYP2C9 and breast cancer: Thus, protective effect of CYP1B1-polymorphisms with doxorubicin and paclitaxel basedchemotherapy induced N-HEM toxicity and CYP2C9- polymorphisms with paclitaxel induced body ache and CYP1A1-polymorphisms with peripheralneuropathy in breast cancer patients.